MDS TALK ON NEUROVISION & AMD
SPEAKERS: Nir Ellenbogen, CEO, NeuroVision Singapore and Allan Fong, Pilot Study Coordinator
DATE & TIME: Saturday, 18 October, 2pm – 3pm
VENUE: 19 Tanglin Road #05-23, Tanglin Shopping Centre, Singapore 247909
CONTACT: Anne at 62387387 or email: alleyes@singnet.com.sg to confirm attendence
The talk will cover the following topics:
EXPLANATION OF NEUROVISION
NeuroVision’s NVCTM vision correction technology enhances eyesight without surgery or medications. It optimizes the performance of the neural or “back end” of the visual system — nothing is changed optically.
The technology has been developed through research focused solely on how the brain processes vision, and is based on two decades of visual neuroscience research.
ABOUT NEUROVISION’S EYE PATHOLOGIES STUDY
With the mission to provide a better quality of functional vision, NeuroVision starts looking into ways to improve vision of individuals who are having reduced central vision due to various eye pathologies such as dry ARMD, Central Serous Retinopathy (CSR) and so on.
NeuroVision, in collaboration with Essilor International and the Singapore Eye Research Institute has started a pilot study to evaluate the efficacy of NeuroVision’s NVC TM – for the vision improvement of people with reduced visual acuity due to various eye pathologies.
Up to 50 participants; aged 10-70 years old; eye pathology stable; having best corrected vision range 6/7.5 to 6/30 due to eye pathologies will be recruited for the study.
Participants will be given a course of NeuroVision treatment sessions (around 30 to 40 sessions in pace of 2-3 times a week) at the NeuroVision Centre located at SNEC and will be followed up for 12 month after the treatment with quarterly vision tests. The study is currently recruiting participants.
SPEAKERS: Nir Ellenbogen, CEO, NeuroVision Singapore and Allan Fong, Pilot Study Coordinator
DATE & TIME: Saturday, 18 October, 2pm – 3pm
VENUE: 19 Tanglin Road #05-23, Tanglin Shopping Centre, Singapore 247909
CONTACT: Anne at 62387387 or email: alleyes@singnet.com.sg to confirm attendence
The talk will cover the following topics:
EXPLANATION OF NEUROVISION
NeuroVision’s NVCTM vision correction technology enhances eyesight without surgery or medications. It optimizes the performance of the neural or “back end” of the visual system — nothing is changed optically.
The technology has been developed through research focused solely on how the brain processes vision, and is based on two decades of visual neuroscience research.
ABOUT NEUROVISION’S EYE PATHOLOGIES STUDY
With the mission to provide a better quality of functional vision, NeuroVision starts looking into ways to improve vision of individuals who are having reduced central vision due to various eye pathologies such as dry ARMD, Central Serous Retinopathy (CSR) and so on.
NeuroVision, in collaboration with Essilor International and the Singapore Eye Research Institute has started a pilot study to evaluate the efficacy of NeuroVision’s NVC TM – for the vision improvement of people with reduced visual acuity due to various eye pathologies.
Up to 50 participants; aged 10-70 years old; eye pathology stable; having best corrected vision range 6/7.5 to 6/30 due to eye pathologies will be recruited for the study.
Participants will be given a course of NeuroVision treatment sessions (around 30 to 40 sessions in pace of 2-3 times a week) at the NeuroVision Centre located at SNEC and will be followed up for 12 month after the treatment with quarterly vision tests. The study is currently recruiting participants.
1 comment:
Would MDS also send an email advising members how to register as participants for this Neurovision study?
Post a Comment